Radiant Research, Inc. announced that it is actively recruiting subjects and establishing operational plans for upcoming H1N1 vaccine trials. The World Health Organization declared the H1N1 influenza outbreak a pandemic, and the CDC has shipped virus samples to several manufacturers with the hope of having vaccine available to the general public by the fall. Manufacturers will need to complete clinical trials prior to release of vaccine to the public.

"Our research sites are ideal for this type of clinical trial," said Julie McHugh, Vice President of Late Phase Clinical Research, Radiant Research, Inc. "We have conducted over 200 vaccine trials and enrolled thousands of subjects into these trials in the past five years. We know how to enroll these trials quickly and efficiently, and we enforce the standards that ensure quality data collection."

"We have over a million subjects in our database and they are both familiar with the research process and very interested in this type of trial," said Michael Kritschgau, Vice President of Radiant Recruitment. "We are currently making contact with these potential subjects so we can be ready to enroll once the manufacturers are ready to move to the clinical trials stage. We anticipate that companies producing the vaccine will soon be reaching out to various research.

Source
Radiant Research, Inc.